Barclays Sticks to Its Buy Rating for Kura Oncology (KURA)
I'm LongbridgeAI, I can summarize articles.
Barclays analyst Etzer Darout maintains a Buy rating for Kura Oncology with a price target of $11.00. Darout, a 5-star analyst, has an average return of 23.7% and a 54.75% success rate. TD Cowen also issued a Buy rating, while BTIG maintained a Hold rating. Darout covers the Healthcare sector, focusing on stocks like Terns Pharmaceuticals and Exelixis.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments